An aging vaccine built from approved drugs, guided by AI.
Takeaways
- Prof. Ronjon Nag, with forty years in AI and an Adjunct Professor of Genetics at Stanford, frames longevity as an engineering problem: reaching one hundred fifty years requires new therapeutics, not lifestyle alone.
- AGEMICA's goal is a vaccine against aging, built by combining roughly 2,500 approved drugs and thousands of Phase 1–2 compounds rather than inventing new chemical entities.
- Machine learning raises the odds: genetic profiling adds roughly forty percent to success probability; biomarker-guided design can triple it versus traditional methods.
- The platform has already validated in cancer, rediscovering known effective therapies, with cell-line and animal studies complete.
- Drawing on COVID-era development speed, the target is full Phase 3 approval in under ten years.
From lab validation to the clinic.
Path forward
- Because the FDA does not classify aging as a disease, AGEMICA starts with age-associated conditions (cancer, cardiovascular disease, and neurodegeneration) while searching for a universal aging signature.
- First drug combinations are identified; the next milestone is an IND submission. Combinations of approved drugs offer a pragmatic path, though the FDA scrutinizes interaction safety closely.
- The XPRIZE Healthspan bar requires measurable efficacy on muscle, cognition, and immune function within one year, tracked via aging clocks, of which roughly eighty now exist across organs and tissues.
- Rollout follows a phased model: older patients with age-related disease first, then cohorts around forty-plus; preventive use in healthy twenty-year-olds is unlikely under current FDA policy.
- A small agile team keeps strategy internal while outsourcing execution to CROs and specialist labs: a moonshot with high regulatory hurdles, but a data-driven path worth building.